ATE318916T1 - Kontrollierte bakterielle lyse zur verabreichung von dna vakzinvektoren und impfantigen - Google Patents

Kontrollierte bakterielle lyse zur verabreichung von dna vakzinvektoren und impfantigen

Info

Publication number
ATE318916T1
ATE318916T1 AT03770256T AT03770256T ATE318916T1 AT E318916 T1 ATE318916 T1 AT E318916T1 AT 03770256 T AT03770256 T AT 03770256T AT 03770256 T AT03770256 T AT 03770256T AT E318916 T1 ATE318916 T1 AT E318916T1
Authority
AT
Austria
Prior art keywords
vaccines
administration
vaccine vectors
dna vaccine
bacterial lysis
Prior art date
Application number
AT03770256T
Other languages
English (en)
Inventor
Roy Curtiss Iii
Wei Kong
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Application granted granted Critical
Publication of ATE318916T1 publication Critical patent/ATE318916T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03770256T 2002-09-01 2003-08-29 Kontrollierte bakterielle lyse zur verabreichung von dna vakzinvektoren und impfantigen ATE318916T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40752202P 2002-09-01 2002-09-01

Publications (1)

Publication Number Publication Date
ATE318916T1 true ATE318916T1 (de) 2006-03-15

Family

ID=31978497

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03770256T ATE318916T1 (de) 2002-09-01 2003-08-29 Kontrollierte bakterielle lyse zur verabreichung von dna vakzinvektoren und impfantigen

Country Status (6)

Country Link
US (1) US20060140975A1 (de)
EP (1) EP1537214B1 (de)
AT (1) ATE318916T1 (de)
AU (1) AU2003278729A1 (de)
DE (1) DE60303810D1 (de)
WO (1) WO2004020643A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0879284B1 (de) * 1996-01-30 2009-07-29 The Regents of The University of California Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung.
WO2005010040A1 (en) * 2003-07-15 2005-02-03 Barros Research Institute Eimeria tenella antigen for immunotherapy of coccidiosis
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
CL2006003000A1 (es) * 2006-11-06 2008-05-02 Univ Pontificia Catolica Chile Procedimiento para obtener proteina tbpb en la superficie de una bacteria gram negativa que comprende construir un plasmido pet con el gen tbpb incorporado; proteina tbpb; antigeno tbpb de la cepa chilena neisseria meningitidis b:4:nt; gen tbpb de la
EP2152883A4 (de) * 2007-05-10 2010-10-27 Univ Arizona Rekombinante bakterien mit vektoren zur expression von nukleinsäuresequenzencodierenden antigenen
WO2009025888A2 (en) 2007-05-10 2009-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
WO2009046449A1 (en) * 2007-10-05 2009-04-09 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
WO2010045620A1 (en) 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US9163219B2 (en) 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
GB2483595B (en) * 2009-05-22 2017-03-29 The Arizona Board Of Regents For And On Behalf Of Arizona State Univ Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) * 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
EP2526185A4 (de) 2010-01-22 2013-07-24 Univ Arizona Bakterium mit einer regulierten rfah-nukleinsäure
US9598697B2 (en) 2010-05-28 2017-03-21 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
WO2012003460A2 (en) 2010-07-02 2012-01-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Compositions and methods for bacterial lysis and neutral lipid production
BRPI1003750A2 (pt) 2010-07-22 2012-04-10 Univ Sao Paulo microrganismos recombinantes, métodos de preparação de linhagens vacinais, antìgenos, composições vacinais vetorizadas, seus usos, anticorpos, kit de diagnóstico e métodos de tratamento e/ou profilaxia
US9127284B2 (en) 2012-05-04 2015-09-08 The University Of Hong Kong Modified bacteria and their uses thereof for the treatment of cancer or tumor
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
US9624214B2 (en) * 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
US10987432B2 (en) * 2013-09-05 2021-04-27 The University Of Hong Kong Therapeutic delivery and expression system, methods and uses thereof
US11103538B2 (en) 2014-08-12 2021-08-31 University Of Massachusetts Targeting epigenetic regulators using a bacterial delivery system
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018018041A1 (en) * 2016-07-22 2018-01-25 University Of Florida Research Foundation, Incorporated Design of protective anti-zikv vaccine without inducing cross-reactions with dengue
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018170147A1 (en) 2017-03-14 2018-09-20 The Regents Of The University Of California Genome-wide identification of immune evasion functions in a virus
CN108410901B (zh) * 2018-02-13 2020-06-30 吉林农业大学 无抗性筛选双抗原锚定表达载体pLQ2a及制备方法
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190495A (en) * 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
US4337314A (en) * 1979-05-23 1982-06-29 Research Corporation Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype
US5877159A (en) * 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US5824538A (en) * 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
US6872547B1 (en) * 2000-10-11 2005-03-29 Washington University Functional balanced-lethal host-vector systems

Also Published As

Publication number Publication date
DE60303810D1 (de) 2006-04-27
WO2004020643A2 (en) 2004-03-11
EP1537214B1 (de) 2006-03-01
AU2003278729A1 (en) 2004-03-19
AU2003278729A8 (en) 2004-03-19
US20060140975A1 (en) 2006-06-29
EP1537214A2 (de) 2005-06-08
WO2004020643A3 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
ATE318916T1 (de) Kontrollierte bakterielle lyse zur verabreichung von dna vakzinvektoren und impfantigen
WO2019126762A3 (en) Cas12a systems, methods, and compositions for targeted rna base editing
EP4253551A3 (de) Neuartige, auf dna und rna gerichtete crispr enzyme und systeme
AU2001265756A1 (en) Sleeping beauty, a transposon vector with a broad host range for the genetic transfprmation in vertebrates
ZA202202628B (en) Novel crispr dna targeting enzymes and systems
PT1487485E (pt) Adjuvantes de imidazoquinolina para vacinas de adn
PH12017502281A1 (en) Thermostable cas9 nucleases
DE69230882D1 (de) Cytosindeaminase negatives selektionssystem zur genübertragung und therapien
HUP0402259A2 (hu) Vakcinák
AU8067698A (en) Chimeric vectors comprising a phage packaging site and a portion derived from a genome of a eukaryotic virus
PH12021550256A1 (en) Novel crispr-associated protein and use thereof
MX2018010288A (es) Sistema de transposon y metodos de uso.
ZA202300378B (en) Gene therapy using nucleic acid constructs comprising methyl cpg binding protein 2 (mecp2) promoter sequences
CU24542B1 (es) Proteínas inhibidoras de insectos provenientes de paenibacillus popilliae
DE69732029D1 (de) Dna enthaltende impfstoffen
WO2004010925A3 (en) Mammalian genes involved in viral infection and tumor suppression
EP1268759A4 (de) Gene der il-12p40untereinheit, welche zur verbesserung der aktivität mutiert ist, und dessen verwendung zur dna vakzinierung
WO2020139152A8 (en) Gene therapy dna vector and its application
WO2004018630A3 (en) Recombinant double-stranded rna phages and uses thereof
Langer et al. Safety assessment of biolistic DNA vaccination
MXPA04003969A (es) Sistema de expresion de acido nucleico regulado.
WO2022130015A3 (en) Processing of tumor infiltrating lymphocytes
ATE293170T1 (de) Phage-abhängige superproduktion von biologisch aktiven proteinen und peptiden
PL370854A1 (en) Ee3-protein family and corresponding dna sequences
Osman et al. Generation of Ag-specific cytotoxic T lymphocytes by DC transfected with in vitro transcribed influenza virus matrix protein (M1) mRNA

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties